ENGNenGene Therapeutics Inc.同业对比
enGene Therapeutics Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENGN本股 | $127M#10 | 0.8x#1 | 0.6x#1 | — | — | -112.7%#11 | — | -50.9%#6 | — | — | -72.9%#13 | — |
| OTLK | $164M#3 | — | — | 116.2x#7 | — | 17.2%#6 | -4744.3%#6 | — | -12.8%#1 | — | -32.2%#7 | — |
| HUMA | $161M#4 | — | 5.1x#10 | 78.8x#6 | — | 72.5%#3 | -5306.0%#7 | -130.6%#9 | — | — | -67.9%#12 | — |
| ARMP | $160M#5 | — | — | — | — | -818.8%#13 | — | — | — | — | 45.3%#2 | 0.1%#1 |
| TNYA | $152M#6 | — | 2.2x#5 | — | — | 18.5%#5 | — | -130.5%#8 | — | — | -48.3%#10 | — |
| CRBU | $140M#7 | — | 1.4x#4 | 12.5x#5 | 11.7%#1 | 0.7%#7 | -1329.4%#5 | -151.0%#10 | — | — | -26.3%#4 | — |
| NMRA | $135M#8 | — | 3.0x#7 | — | — | -2.8%#9 | — | 532.2%#2 | -594.0%#2 | — | -54.1%#11 | — |
| LENZ | $129M#9 | — | 0.6x#2 | 6.7x#4 | — | -65.0%#10 | -477.5%#4 | -37.5%#5 | — | — | -90.2%#14 | — |
| ATTO | $1.1B#1 | — | — | — | — | — | — | — | — | — | 368.5%#1 | — |
| BDTX | $111M#11 | — | 1.2x#3 | 1.6x#2 | — | 132.1%#2 | 17.9%#2 | 23276.9%#1 | — | — | -42.5%#9 | — |
| CRDF | $102M#12 | — | 3.8x#9 | 171.9x#8 | -13.2%#3 | -0.9%#8 | -8256.3%#8 | -0.2%#4 | — | — | -39.4%#8 | — |
| CGTX | $100M#13 | — | 3.0x#6 | — | — | 30.9%#4 | — | -71.1%#7 | — | — | -28.3%#6 | — |
| ATRA | $98M#14 | — | — | 0.8x#1 | -6.3%#2 | 138.3%#1 | 29.7%#1 | — | — | — | -16.0%#3 | — |
| BSEM | $94M#15 | — | 3.4x#8 | — | — | — | — | 0.0%#3 | — | — | — | — |
| PTHS | $88M#16 | — | — | 5.2x#3 | — | -444.6%#12 | -193.1%#3 | — | — | — | -27.3%#5 | — |
| SCTX | $651M#2 | — | — | — | — | — | — | — | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-18。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议